CTKB
Cytek BioSciences Inc

170
Loading...
Loading...
News
all
press releases
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates
chainwire·4mo ago
News Placeholder
Preview: Cytek Biosciences's Earnings
read more...
Benzinga·10mo ago
News Placeholder
Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)
Piper Sandler analyst David Westenberg maintained a Buy rating on Cytek Biosciences (CTKB Research Report) today and set a price target of $8.00...
TipRanks Financial Blog·1y ago
News Placeholder
Insider Sell: Cytek Biosciences Inc's (CTKB) Chief Technology Officer Ming Yan Sells 40,000 Shares
Related Stocks: CTKB...
GuruFocus·1y ago
News Placeholder
Cytek Biosciences Names William McCombe Chief Financial Officer
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek...
Globe Newswire·1y ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) PT Lowered to $10.00
Cytek Biosciences (NASDAQ:CTKB Get Free Report) had its target price cut by equities researchers at Piper Sandler from $11.00 to $10.00 in a report issued on Wednesday, Benzinga reports. The...
Zolmax·2y ago
News Placeholder
Cytek Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
Cytek Wuxi Facility Cytek's new 50,000-square-foot facility in Wuxi, China increases the company's manufacturing capacity to meet the growing worldwide demand for comprehensive cell...
Globe Newswire·2y ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Trading Down 6.5% on Analyst Downgrade
Cytek Biosciences, Inc. (NASDAQ:CTKB Get Free Report)s stock price dropped 6.5% during mid-day trading on Wednesday after Piper Sandler lowered their price target on the stock from...
Zolmax·2y ago
News Placeholder
Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)
In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Cytek Biosciences (CTKB Research Report), with a price...
TipRanks Financial Blog·2y ago

Latest CTKB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.